We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple Paper Test Offers Early Cancer Diagnosis

By LabMedica International staff writers
Posted on 04 Jun 2025

Diagnosing cancer at an early stage remains a significant clinical challenge, particularly in resource-limited settings where access to advanced testing equipment is scarce. More...

Conventional detection methods often struggle to identify cancer-related biomarkers at low concentrations, especially in the early phases of disease. Now, a team of engineers has developed a novel nanoparticle-based sensor that can detect cancer through a simple urine test, offering a potentially affordable, accessible, and rapid diagnostic solution.

The new diagnostic system developed at Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) relies on nanoparticles engineered to respond to tumor-specific enzymes. When these particles reach a tumor, they release short DNA sequences—known as “barcodes”—into the bloodstream, which are later excreted in urine. These DNA barcodes can then be analyzed using a paper-based test strip, similar to at-home COVID-19 tests, using CRISPR technology. A dark line appears when a specific barcode is detected, signaling the presence of cancer-related enzyme activity. To protect the barcodes from degradation in the blood, the researchers used a phosphorothioate modification—a method already applied in stabilizing modern RNA vaccines. Each DNA barcode is linked to a nanoparticle by a cleavable linker responsive to a specific protease—enzymes involved in tumor progression. Once released, the barcode circulates and is ultimately excreted in urine.

The researchers used two types of nanoparticles: one based on FDA-approved polymers and another built from nanobodies—antibody fragments that home in on tumors. The test was designed for multiplexing, meaning it can detect multiple enzyme activities in a single sample, improving both sensitivity and specificity. In research published in Nature Nanotechnology, the scientists used mouse models to demonstrate that five DNA barcodes could accurately distinguish between tumors originating in the lungs and colorectal cancer that had metastasized to the lungs. Additionally, the team designed a microfluidic chip capable of reading up to 46 different DNA barcodes from one sample. These capabilities suggest the test could eventually classify cancer types, monitor treatment responses, and detect recurrence. The broader goal is to make the test scalable and suitable for use in humans. Phase 1 clinical trials conducted of an earlier version of the urinary diagnostic particles has demonstrated their safety in patients.

“We are trying to innovate in a context of making technology available to low- and middle-resource settings,” said MIT scientist Sangeeta Bhatia. “Putting this diagnostic on paper is part of our goal of democratizing diagnostics and creating inexpensive technologies that can give you a fast answer at the point of care.”


New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.